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Risk Stratification

Non-Q Wave Myocardial Infarction
Steven Borzak, MD,* and Howard S. Rosman, MD*

Non-Q wave myocardial infarction is a distinct and changing clinical entity characterized hy lower
initial mortality and a higher rate of reinfarction compared to Q wave infarction. Clinical and
pathologic data suggest that the syndrome resuhsfromtransient or incomplete coronary occlusion
resulting in an infarct which is smaller than when Q waves are present. High-risk patients can
be identified during hospitalization, allowing for aggressive therapy aimed at revascularization.
Relatively few clinical trials have examined initial therapy or secondaiy prevention in this group of
patients. These studies are reviewed and management guidelines suggested. (Heniy Ford Hosp Med
J 1991:39:256-62)

I

n 1919, Herrick (1) published a report of three patients who
survived acute coronary thrombosis. He displayed the ECG
of one patient where T-wave abnormalities, but no Q waves,
were present. This was the first published illustration of what is
now referred to as a non-Q wave myocardial infarction (MI).
One year later, Pardee (2) described a patient with MI whose
ECG initially demonstrated pathological ST segment elevation
with subsequenl development of a "deep S" wave. For decades
this deep S wave (later called a Q wave) was the finding clinicians considered pathognomonic of infarction.
In 1942, Langendorf and Kovitz (3) reported a patient with
clinical evidence of Ml after hip surgery, where ECGs failed
to show Q waves. At autopsy, the zone of infarction did not involve the endocardium, leading the investigators to postulate
that ST and T-wave changes in the absence of Q waves were
markers for subendocardial infarction. In 1954, Prinzmetal et al
(4) suggested that the subendocardium was relatively "silent"
electrocardiographically in dogs subjected to experimental ischemia. This report advanced the practice of referring to infarctions with Q waves as "transmural" and to infarctions with ST
or T-wave changes but no Q waves as "subendocardial." Later
findings by the same group invalidating the initial results went
unnoticed (5). This terminology persisted despite clear evidence, most recently assembled by Spodick (6), that extent of
infarction does not correlate with presence or absence of Q
waves. Therefore, most investigators currentiy classify infarctions into electrocardiographic categories of "Q" versus "nonQ" rather than using the imprecise pathologic descriptors of
"transmural" versus "nontransmural."

Pathophysiology
In 1980, DeWood and colleagues (7) settled a long-standing
controversy by proving coronary thrombosis causative in the
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pathogenesis of infarction, rather than a secondary event. They
performed eariy angiography in patients with infarction, which
revealed a high incidence of thrombosis. In contrast, in 1986 the
same group analyzed eariy angiograms of patients with non-Q
wave Ml and showed a much lower incidence of coronary occlusion and a higher incidence of collateralization of the infarct
vessel (8). The finding of a patent infarct vessel has been reported by other groups when patients were studied within two
weeks after non-Q wave Ml (9,10). Pathologic studies conducted by Davies and Thomas (11) have revealed that plaque
fissure is common in initiating the sequence of events triggering
the coagulation cascade and leading to thrombosis at the site of
a fixed coronary obstruction.
Reconciling the evidence of coronary thrombosis as the proximate cause of infarction with catheterization studies in patients
showing open infarct-related arteries after non-Q wave MI has
led to several hypotheses on the mechanism of non-Q wave MI
(Table 1). The angioscopic visualization of dynamic, forming,
and dissolving thrombus in the coronaries of patients with "intermediate" and unstable coronary syndromes (12) suggested
that not all intracoronary thrombi are permanent and has led to
the favored hypothesis that non-Q wave Ml may be most often
the result of transient coronary occlusion by thrombus.
A number of lines of evidence have been marshalled by Gibson (13) favoring coronary occlusion followed by reperfusion as
the most common mechanism of non-Q wave MI. First, pathologic studies by Freifeld et al (14) showed that patients dying of
non-Q wave MI more often had patent infarct vessels and were
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Table 1
Proposed Pathophysiological Mechanisms
of Non-Q Wave Myocardial Infarction
Occlusion-repert'usion of infarct vessel:
• Spontaneous lysis of obstructive coronary thrombus
• Relief of spasm which had cau,sed coronary occlusion
• Both
Incomplete occlusion of infarct vessel by plaque/thrombus
Increased demand in setting of fixed coronary obstruction
Occlusion of infarct vessel with low-grade collateral flow

twice as likely to manifest contraction band necrosis, a histologic feature of reperfusion, when compared with patients dying
of similar-sized Q wave infarcts. Second, non-Q wave Mls tend
to be smaller, with an earlier peak of serum creatine kinase MB
(CK-MB), a serologic pattem suggesting "washout" of the enzyme in a reperfused zone similar to that observed after successful treatment with thrombolytic agents (13). One trial reported
that of 53 consecutive patients given streptokinase (SK) for
acute chest pain and ST elevation on the ECG, eight ultimately
developed non-Q wave Ml; six of the eight were treated within
1.5 hours of the onset of symptoms (15). Finally, Huey and colleagues (9) showed that up to one-half of patients who ultimately develop non-Q wave Ml without thrombolytic treatment
present with ST elevation on the initial ECG, a pattem previously thought to lead inevitably to Q wave development. These
findings have subsequently been confirmed by others (10,16,
17). While it could be argued that ST elevation may not signify
complete coronary occlusion, this finding together with the
above arguments and other insights gained since the advent of
the "thrombolytic era" suggest that non-Q wave MI differs from
Q wave Ml not as much in the initiating sequence of intracoronary thrombosis but more in the subsequent fate of the occluding thrombus. These studies also suggest that early thrombolytic
therapy may "convert" a potential Q wave infarction into a nonQ wave MI. Thus, patients with non-Q wave MI in the 1990s
may be a different group than those studied in earlier years, before the general use of the more sensitive and specific CK-MB
enzyme assay to detect infarction (early 1980s) (18,19) and
prior to the increased application of thrombolytic therapy (mid
1980s). This may explain why the incidence of non-Q wave Ml
is increasing (18,20); non-Q wave Ml patients now account for
more than 40% of all patients with MI at some institutions (21).
Further research may help define anatomic, hematologic, and
demographic characteristics that produce the differing rates of
acute coronary occlusion in the Q wave and non-Q wave MI
syndromes.

Natural History and Clinical Syndrome
of Non-Q Wave MI
ECG criteria for non-Q wave MI
Q wave infarctions are characterized by the development of
30-msec or longer Q waves in at least two consecutive leads of
the anterior (V1-V4), inferior (II, III, aVF), or lateral (1, aVL,
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Table 2
Clinical Profile of Q Wave Versus
Non-Q Wave Myocardial Infarction Patients*
QWave
MI
Short-term mortality
(5 to 30 days)
Long-term mortality
(12 to 96 months)
Reinfarction
(hospital stay-44 months)

209;

Non-Q
Wave MI

Number
of Studies

10%

24

31%

21

16%

14

*Pooled data from Gibson (13),
MI = myocardial infarction.

V5, V6) distributions. Posterior infarctions characterized by
prominent R waves and R/S ratio > 1 in leads VI-V2 are usually
categorized as Q wave equivalent, as are anterior infarctions
where "embryonic" R waves of less than 0.25 mm develop in
VI-V4 (22). Presenting ECGs of patients with non-Q wave infarction may show initial ST elevation (9,10,16,17), in which
case the diagnosis of non-Q wave MI must await subsequent
evolution of the ECG over 24 to 48 hours. Patients with prolonged chest pain and ST depression or T-wave inversion on the
initial ECG may initially be suspected of having non-Q wave
MI. but distinction from unstable anginal syndromes must await
serologic confirmation of infarction by CK-MB determination
and clinical course.
Clinical course and prognosis of non-Q wave MI
Course and prognosis differ between patients who do and do
not manifest Q waves after infarction. The many studies comparing clinical characteristics of Q wave and non-Q wave MI patients published between 1970 and 1983 have been extensively
reviewed by Gibson (13). Appreciable differences have not been
found regarding patients' demographic characteristics. The key
question posed by nearly all of the studies is: Does the prognosis
of Q wave and non-Q wave MI patients differ in terms of death
or reinfarction? The synthesis of Gibson's review of these studies is shown in Table 2. Event rates for mortality and reinfarction were obtained by pooling the results in Q wave and non-Q
wave MI groups. Not all studies showed a statistically significant difference between groups for the variables shown, but aggregate differences are highlighted. Non-Q wave MI patients
had lower short-term mortalily (10% versus 20%) but similar or
slightiy higher long-term mortality (32% versus 26%). This discrepancy may be explained by the fact that nearly every study
reviewed showed that non-Q wave Ml patients have a smallersized infarct. More frequent reinfarction in non-Q wave MI
(16% versus 6% in Q wave MI), sometimes fatal, would tend to
equalize the long-term mortality rates.

In-hospital Evaluation of Non-Q Wave
MI Patients: Risk Assessment
Patients with non-Q wave MI are a heterogeneous group regarding demographic characteristics, prior cardiac symptoms.
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underlying coronary anatomy, ventricular function impairment,
and, in particular, risk for future events (21). Some clinicians
recommend lhal all non-Q wave Ml patients undergo coronary
angiography with consideration toward revascularization (23),
while others suggest that a noninvasive assessment can identify
patients at lower risk for death and reinfarction who would then
be managed expectantly without routine angiography (13,24).
We recommend the latter approach, based on I) the lack of clinical trials showing benefit to patients of one approach over the
other, and 2) the results of several trials of thrombolytic therapy
in patients presenting with ST segment elevation. The Thrombolysis in Myocardial Infarction, phase IIB (TIMI-IIB) study
showed that in patients who had been treated with thrombolysis,
a group which differs somewhat from patients with non-Q wave
Ml, no benefit was achieved by requisite angiography and percutaneous transluminal coronary angioplasty (PTCA) in the absence of recurrent ischemia (25).
Recurrent or provokable ischemia
Numerous studies have shown that recurrent spontaneous or
provoked ischemia dramatically increases the risk of early reinfarction and death in patients after a Q wave or an unspecified
type of infarction (26). Similarly, in patients with non-Q wave
MI, spontaneous postinfarction angina has been identified as a
powerful predictor of subsequent events. Analysis of clinical
features of the 576 patients enrolled in the multicenter Diltiazem
Reinfarction Study (DRS) (22) revealed that the 43% of patients
who had recurrent angina during the 14-day in-hospital followup period had a nearly fourfold higher risk of reinfarction
(12.2% versus 3.6%) and death (6.1% versus 1.5%) when compared with patients not experiencing angina (27). Furthermore,
patients whose angina was associated with ST or T-wave
changes were 3.8 times more likely to have reinfarction and 7.5
times more likely to die compared to patients with angina not
manifesting transient ECG changes (27). Reinfarction itself was
also a powerful predictor of in-hospital death: 16.7% of patients
with reinfarction died as compared to 2.4% of patients without
reinfarction (22). When comparing all non-Q wave Ml patients,
Maisel et al (28) also found that patients with reinfarction had a
higher in-hospital mortality (43% versus 8%) and one-year mortality (65% versus 16%) than those without reinfarction.

had a 3.8-fold relative risk of death and a 4.1-fold risk of reinfarction compared with inferior-lateral location. In a retrospective analysis of patients in the Multicenter Investigation of the
Limitation of Infarct Size study. Stone et al (29) confirmed that
anterior location conferred a worse prognosis than inferior location, even when data were adjusted to compare infarcts of similar size as determined by magnitude of peak CK release. Kao
and colleagues (21) hypothesized that anterior infarcts in the left
anterior descending (LAD) artery distribution may be more
likely to have larger areas of residual ischemic myocardium than
infarcts in the inferior location with the smaller distribution
zones of right or left circumflex arteries. In addition, congestive
heart failure, another risk factor for mortality, is more likely to
occur at presentation or develop in the setting of an anterior infarct (29).
Impaired ventricular function
Clinical signs of heart failure as well as objective evidence of
diminished ejection fraction are correlated with adverse outcomes following non-Q wave MI (17,29,30). Congestive heart
failure was a univariate predictor of reinfarction and mortality in
the 576 patients enrolled in the DRS. and this variable remained
an independent predictor of both outcomes after Cox multiple
regression analysis (30). Subset analysis of the Multicenter Diltiazem Postinfarction Trial dichotomized patients based on the
presence or absence of pulmonary congestion and revealed that
this clinical finding was a risk factor for reinfarction and cardiac
death following non-Q wave MI. Furthermore, diltiazem administration led to an increa.se in death and reinfarction compared
with placebo in this subset of patients (31). These findings support the already established importance of left ventricular (LV)
function as the best predictor of outcome in patients with Q
wave or unspecified infarction (26).

Electrocardiographic findings
A numberof studies have shown that non-Q wave MI patients
whose initial ECGs manifest ST depression are at greater risk
of death or reinfarction (16.30,32,33). One-year mortality was
29%' versus 11 % when ST depression versus ST elevation was
found on the initial ECG (16). However, initial ST depression
often coexists with LV functional impairment (32,33). To invesEvidence of ischemia provoked by predischarge submaximal
exercise testing is also a predictor of increasedriskof f uture car- tigate whether ST depression was an independent predictor of
adverse outcome, Schechtman and colleagues (30) using Cox
diac events. In a prospective study of 87 patients with non-Q
wave MI, Gibson et al (10) found that 36% of patients had ST multiple regression analysis identified baseline and discharge
depression, 30% had angina, and 60% had a redistribution thal- ST depression as univariate predictors of one-year reinfarction
and mortality but not of in-hospital reinfarction or mortality in
lium defect on submaximal predischarge treadmill testing. Subsequently, over a median duration of 30 months of follow-up, 14 the DRS population (31). The finding of persistent ST depresofthe 16 reinfarctions involved the infarct zone and all occurred sion was the single most powerful independent predictor of both
endpoints among all 24 variables examined. ST elevation prein patients whose predischarge study had a redistribution thalsent at discharge also predicted late mortality but not reinfarclium defect (10).
tion.
Anterior versus inferior-lateral location
Several studies have shown that patients with anterior non-Q
wave MI are more likely to experience future adverse events.
Kao et al (21) analyzed consecutive cardiac care unit admissions
and found that in 135 patients, anterior non-Q wave Ml location

258

Henry Ford Hosp Med J—Vol 39, Nos 3 & 4, 1991

The electrocardiographic diagnosis of LV hypertrophy has
been shown in population-based studies to be independently associated with an increased risk of sudden death and acute MI
(34). This relationship was confirmed in the non-Q wave MI
population, where multivariate analysis of the DRS study popu-
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Table 3
Clinical Predictors of Death or Reinfartion
Death

Reinfarction

ST-T changes
compatible with
ischemia

References

Angina

Angina

19,22

Anterior location
CHF

Anterior location
CHF

21,29
17,21,31
16,31,33,34

ST depression

ST depression

LVH
Reinfarction

LVH

17,31
22,28

Positive predischarge ETT

10

CHF = congestive heart failure, LVH
treadmill lesl.

History of chest
pain after >24
hours

Development of signs or
symptoms of CHF: EF
<50%

Anterior

infarction

Ventricular tachycardia
or fibrillation

left ventricular hypertrophy, ETT :

Predischarge ETT
positive for ischemic

lation showed a twofold higher incidence of death and reinfarction at one-year follow-up (31).
Catheterization

Diagnostic Approach to the Non-Q Wave
MI Patient
A recommended approach for diagnostic evaluation of the
non-Q wave MI patient is based on the concept of risk stratification (Table 3). This scheme is illustrated in the Figure. This approach would allow for expectant management of an uncomplicated patient at lower risk, while providing an aggressive posture when death or reinfarction is relatively more likely. We do
note that no prospective study has shown improved clinical outcomes after revascularization, whether by coronary artery bypass grafting (CABG) or PTCA in non-Q wave M l patients.
Nevertheless, a consensus favors such mechanical intervention
when severe or unstable symptoms or high-risk clinical situations are present (13,23,24).

Close observation

Catheterization

Figure—Algorithm for in-hospital evaluation (rf the non-Q
wave MI patient. The treatment strategy is based on the presence or absence of high-risk clinical markers. See text for details.

While the appearance of complex ventricular ectopy was
found to occur in 22% of non-Q wave MI patients in one series,
this study did not differentiate sustained or symptomiatic ventricular tachycardia or fibrillation from lower grade arrhythmias, nor did it find that ventricular ectopy predicted subsequent
events (10). However, the small sample size of this subgroup
makes a type II error possible. Because late (occurring after the
first 24 hours) sustained or symptomatic ventricular tachycardia
or fibrillation occurring in the absence of electrolyte disturbance
Bedside assessment
or severe LV dysfunction may signify ischemia, we feel that this
An especially vigilant approach is warranted given the tenset of circumstances warrants coronary angiography. Continudency for non-Q wave MI patients to experience recurrent anous bedside and/or bolter monitoring is recommended for the
gina, infarction, and death as described previously. In particular,
first 48 to 72 hours after symptom onset (35).
patients should be questioned daily about the development of
The submaximal exercise test has become the standard of care
ischemic or congestive heart fatiure symptoms. The physical exfor
MI patients prior to discharge who do not experience an inamination should focus on the development of tachycardia, hyhospital
complication (26). If resting ST abnormalities such as
potension, pulmonary rales, or new gallop rhythms. A subtie deLV
hypertrophy
or digitalis effect preclude interpretation of exterioration in ventricular function in a resting, asymptomatic paercise-induced
ECG
changes, then thallium imaging is recomtient may be the only sign of recurrent ischemia or infarction.
mended
(35).
Patients
who manifest ischemia by the developThe appearance of any of these findings justifies a repeat ECG to
ment
of
angina,
ECG
changes,
or diagnostic thallium alterations
look for new ischemic changes.
can then be referred for angiography.
Noninvasive assessment
Since significant impairment of LV function can be asymptomatic or compensated by medical therapy, we believe an objective assessment of LV function by echocardiography or radionuclide ventriculography is warranted prior to discharge. Patients with impaired LV function are more likely to have multivessel coronary disease and would be most likely to benefit
from mechanical revascularization (35).
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Invasive assessment
Once a patient has been identified as high risk, catheterization
with coronary angiography is recommended (Table 4). The goal
of this procedure is to define coronary anatomy in consideration
of revascularization by PTCA or CABG. Accordingly, a relative
contraindication to catheterization would be a patient's unwillingness to consider either revascularization procedure.
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Table 4
In-hospital Evaluation of Patients with
Non-Q Wave Myocardial Infarction
Procedure
Daily bedside
examination
Telemetry or Holler
monitoring (at least
72 hours)
Echocardiography or
radionuclide
ventriculogram
Predischarge ECG
Submaximal
predischarge
exercise test
Coronary angiography

Inclusion
All patients
All patients
All patients

Patients without
prior indication
for angiography
Patients without
prior indication
for angiography
See Figure

Purpose
Assess for recurrent
angina or CHF
Detect "late" ventricular
tachycardia or fibrillation
Determine overall ventricular
function and regional
contractility
Detect persistent or new
ST depression
Detect exercise-induced
ischemia
Define coronary anatomy prior
to possible revascularization

Treatment of Non-Q Wave MI Patients
Thrombolytic therapy
No study to date has conclusively reported the effect of
thrombolytic therapy on death or reinfarction after non-Q wave
Ml. Such a study might be impossible to conduct because ofthe
variability in presenting features seen in non-Q wave MI patients. Up lo one-half of non-Q wave MI patients present with
ST elevation on ECG, which is a general criterion for administration of thrombolytic therapy (25). Many patients who later
develop a non-Q wave MI might initially be classified as having
a transmural injury currentiy typical of an evolving Q wave infarct (9). Non-Q wave MI patients presenting with ST depression or T-wave inversion cannot be reliably distinguished from
patients with unstable angina until CK-MB results and clinical
course are apparent. The TIMI-IIIB study currentiy in progress
is designed to compare low-dose tissue plasminogen activator
with placebo in patients with chest pain and ECG changes other
than new ST elevation or Q waves, but without enzymatic evidence of infarction; some of these patients are likely to develop
non-Q wave Ml. Thus non-Q wave MI patients are now more
likely either to be given lytic therapy upon presentation with ST
elevation or be managed without thrombolysis if presenlalion is
with ST depression or T-wave inversion. Recommendations for
lytic therapy in the latter group of patients must await the results
of TIMI-llIB and other trials.
Heparin and acetylsalicylic acid
No trial has examined the role of either intravenous (IV) heparin or acetylsalicylic acid (ASA) as primary treatment for patients with non-Q wave MI. Lxtw-dose subcutaneous heparin has
been recommended after infarction to prevenl venous thrombosis and pulmonary embolism (35). Therapeutic IV heparin has
been shown to be of benefit in unstable angina (22), and since a
common pathophysiology has been proposed for unstable angina and non-Q wave MI (36), some investigators have advocated the use of this agent on presentation and for several days
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after non-Q wave MI. Heparin may be even more appealing with
the knowledge that most infarct-related vessels are patent at
angiography and that most reinfarctions occur in the same arterial distribution (10), but a firm recommendation cannot be
made in the absence of a clinical trial. IV heparin followed by
oral anticoagulation can be recommended when non-Q wave Ml
is accompanied by severe global hypokinesis, significant anterior akinesis, or directiy visualized mural thrombus (35).
ASA has been shown to reduce mortality and reinfarction in
unstable angina (37), but no trial has assessed prospectively its
effect on modifying myocardial damage in patients with non-Q
wave MI. Again, based on the postulated common pathophysiologic mechanisms of these two clinical entities, early ASA
therapy is appealing. A much stronger argument can be made for
ASA treatment in secondary prevention of future events.
Anti-ischemic therapy
Recurrent angina after non-Q wave MI should be promptiy
treated, followed by coronary angiography. There is littie to
suggest relative benefits of calcium channel blocking agents
over (3-adrenergic receptor blocking agents (beta-blockers)
when ischemia recurs in the days after non-Q wave MI.
IV nitroglycerin has found growing support for its potential
role in limiting infarct size and reducing mortality in patients
with unspecified infarction (38,39). However, no study has addressed the non-Q wave MI population and current recommendations of the American College of Cardiology do not support
IV nitroglycerin in all patients with infarction (35). Nitroglycerin is well established for relieving ischemic symptoms. Analgesia with morphine sulfate and sedation with short-acting benzodiazepines are appropriate for many patients experiencing angina.
Revascularization
No study has examined the effect of either PTCA or CABG
on symptoms or survival after non-Q wave MI. When recurrent
ischemia or infarction occurs, there is general agreement among
cardiologists that catheterization followed by mechanical revascularization offers the best hope both for relief of symptoms and
protection from further ischemia and infarction (13,24). Such an
approach is particularly warranted when the jeopardized myocardium is in the anterior distribution of the LAD artery (16).

Secondary Prevention After Non-Q Wave MI
An important issue distinct from management of recurrent
ischemia is routine prophylactic treatment of patients who are
asymptomatic after non-Q wave MI (Table 5).
ASA and anticoagulation
ASA has been shown in a number of trials to reduce both
death and reinfarction after unspecified infarction and should be
given to patients after non-Q wave MI when no contraindications are present (37). Subgroup analysis of the Persantine-Aspirin Reinfarction Study suggested that the beneficial effects of
antiplatelet therapy may be even more pronounced for non-Q
wave MI than for Q wave Ml patients (40).
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Table 5
In-hospital Treatment of Non-Q Wave
Myocardial Infarction Patients*
Status of

Indication
Primary modification
of infarction

Secondary prevention of
death or reinfarction

Treatment
Thrombolytic therapy
Heparin
ASA
Nitrates
Beta-blockers
Calcium blockers
ASA
Beta-blockers
Calcium blockers
Warfarin

Recommendation
Controversial
Controversial
Recommended
Acceptable
Acceptable
Controversial
Recommended
Acceptable
Acceptable
Controversial

*For references, see text.

While anticoagulation with warfarin was shown in a recent
study to reduce death after unspecified infarction (41), routine
administration to non-Q wave M l patients cannot be recommended in the absence of more traditional indications (visualized mural thrombus, akinetic anterior wall, atrial fibrillation).
Calcium channel blockers and the DRS
The DRS is the only published trial designed to examine secondary prevention specifically in the population of non-Q wave
MI patients (22). A total of 576 patients were enrolled 24 to 72
hours after the index event and randomized to the double-blind
administration of diltiazem or placebo. Patients were followed
until discharge (a total of 14 days) and evaluated for the primary
endpoint of reinfarction and secondary endpoints of recurrent
angina and in-hospital mortality. Diltiazem was found to reduce
early reinfarction from 9.3% in control patients to 5.2% in those
receiving diltiazem (P < 0.03). The validity of this finding has
been questioned, however, because a one-sided test of significance used in this analysis would not adequately account for the
possibility of an adverse effect of treatment. Diltiazem had no
significant effect on recurrent angina (41% versus 44% in placebo-treated patients) or on in-hospital mortality (3.8% versus
3.1% in the placebo group). Episodes of severe angina (requiring withdrawal from the trial for indicated calcium channel
blockers or revascularization) were significantly reduced by
50%. No late follow-up on treatment effect was provided in the
study. We note also that nearly two-thirds of patients in both
treatment and control groups were receiving beta-blockers,
which were not restricted by the study design.
A retrospective analysis of non-Q wave MI patients has been
performed on results from the Multicenter Diltiazem Postinfarction Trial (31). This study was designed to examine the longterm effects of diltiazem from 3 to 15 days after unspecified infarction, with follow-up to an average of 25 months. Diltiazem
had no effect on mortality or cardiac event rate overall (42), but
subgroup post hoc analysis showed fewer cardiac events and a
trend toward lower mortality in patients receiving diltiazem after a first non-Q wave MI. A detrimental effect was seen in all
subgroups with pulmonary congestion as a manifestation of
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congestive heart failure (31). However, retrospective subgroup
analysis has serious limitations in identifying treatment indications not originally specified by the study design (43).
Other calcium channel blocking agents (verapamil, nifedipine, and newer "second generation" agents) have not been examined specifically in non-Q wave Ml patients. We conclude
that data support the safe use of diltiazem for secondary prevention after non-Q wave Ml in patients without congestive heart
failure (35) but that unequivocal evidence of important benefit
is lacking.
Beta-blocking agents
The use of beta-blocking agents after unspecified infarction
has been found to reduce significantly both mortality and reinfarction; their administration has been recommended for at least
two years after a MI (35). No trial has prospectively examined
the non-Q wave Ml population, but subset analysis of three
studies—Metoprolol in Myocardial Infarction Study, the BetaBlocker Heart Attack Trial, and the Timolol Myocardial Infarction Study—has yielded conflicting results, with only the latter
study showing a statistically significanl decrease in mortality
but not reinfarction (44-46). The limitations of post hoc analysis
have been extensively discussed in this context (43). Given the
relative instability of the non-Q wave Ml population compared
to patients with Q wave infarcts, some investigators have argued
that prophylactic beta-blockade might in fact be more beneficial
in this subgroup. An answer to this intriguing issue must await a
prospective trial.
Revascularization
No trial supports PTCA or CABG in asymptomatic patients
following non-Q wave MI (13). We support the use of the predischarge treadmill test to direct patients who manifest exerciseinduced ischemia toward catheterization and revascularization
when appropriate.

Summary and Conclusions
Changes in medical practice in the 1990s—among them a
better pathophysiologic understanding of the role of intracoronary thrombus and increased use of thrombolytic therapy in
the early hours of MI—^have changed the types and numbers of
patients with the diagnosis of non-Q wave MI. Prior experience
has shown that non-Q wave MI patients experience smaller infarcts, higher rates of reinfarction, and lower in-hospital mortality compared to Q wave MI patients. In-hospital management
should focus on an aggressive search for spontaneous or provokable ischemia, depressed LV function, and other markers of
increased risk of future events. Such patients should be considered for angiography and revascularization. Few clinical studies
support specific secondary prevention strategies in this population other than those measures recommended for the postinfarction population at large. Firm recommendations for therapy
must await future trials.
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